Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited Fundamental Analysis
Hansoh Pharmaceutical Group Company Limited (3692.HK) shows moderate financial fundamentals with a PE ratio of 43.04, profit margin of 36.25%, and ROE of 16.00%. The company generates $13.4B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 76.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 3692.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent3692.HK demonstrates superior asset utilization.
Valuation Score
Weak3692.HK trades at a premium to fair value.
Growth Score
Moderate3692.HK shows steady but slowing expansion.
Financial Health Score
Excellent3692.HK maintains a strong and stable balance sheet.
Profitability Score
Excellent3692.HK achieves industry-leading margins.
Key Financial Metrics
Is 3692.HK Expensive or Cheap?
P/E Ratio
3692.HK trades at 43.04 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 3692.HK's PEG of 5.18 indicates potential overvaluation.
Price to Book
The market values Hansoh Pharmaceutical Group Company Limited at 6.62 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 49.33 times EBITDA. This signals the market has high growth expectations.
How Well Does 3692.HK Make Money?
Net Profit Margin
For every $100 in sales, Hansoh Pharmaceutical Group Company Limited keeps $36.25 as profit after all expenses.
Operating Margin
Core operations generate 33.80 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $16.00 in profit for every $100 of shareholder equity.
ROA
Hansoh Pharmaceutical Group Company Limited generates $13.63 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Hansoh Pharmaceutical Group Company Limited generates limited operating cash flow of $1.20B, signaling weaker underlying cash strength.
Free Cash Flow
Hansoh Pharmaceutical Group Company Limited produces free cash flow of $1.08B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.18 in free cash annually.
FCF Yield
3692.HK converts 0.51% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
43.04
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
5.18
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.62
vs 25 benchmark
P/S Ratio
Price to sales ratio
15.86
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.004
vs 25 benchmark
Current Ratio
Current assets to current liabilities
8.56
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.16
vs 25 benchmark
ROA
Return on assets percentage
0.14
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How 3692.HK Stacks Against Its Sector Peers
| Metric | 3692.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 43.04 | 28.45 | Worse (Expensive) |
| ROE | 16.00% | 763.00% | Weak |
| Net Margin | 36.25% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 8.56 | 2795.60 | Strong Liquidity |
| ROA | 13.63% | -16588.00% (disorted) | Strong |
3692.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Hansoh Pharmaceutical Group Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation